今日盘中，东曜药业-B（01875）股价大幅下跌7.63%，引发市场关注。这一显著跌幅很可能与公司最新发布的2025年中期业绩报告有关。
根据东曜药业-B于昨日晚间发布的2025年中期财报，公司收益为4.89亿元人民币，同比下降6%。更值得注意的是，公司净利润仅为406.2万元人民币，同比大幅下滑87.13%。每股盈利降至0.01元人民币，公司决定不派发中期股息。
尽管公司在CDMO（合同开发和生产组织）业务方面取得了一些进展，如新增项目16个，其中ADC项目14个，累计项目数达到169个，但这些积极因素似乎未能抵消投资者对业绩大幅下滑的担忧。市场对东曜药业-B短期盈利能力的担忧可能是导致股价大跌的主要原因。投资者需密切关注公司未来的业务发展和盈利改善情况。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.